{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:33:35Z","timestamp":1770294815882,"version":"3.49.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.clinthera.2008.02.011","type":"journal-article","created":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T15:11:31Z","timestamp":1208445091000},"page":"231-248","source":"Crossref","is-referenced-by-count":28,"title":["Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia"],"prefix":"10.1016","volume":"30","author":[{"given":"Jill A.","family":"Fowler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawny L.","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami R.","family":"Argo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.02.011_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"10.1016\/j.clinthera.2008.02.011_bib2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","article-title":"Serotonin-dopamine interaction and its relevance to schizophrenia","volume":"153","author":"Kapur","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4088\/JCP.v67n0401","article-title":"Atypical antipsychotics in the treatment of mania: A meta-analysis of randomized, placebo-controlled trials","volume":"67","author":"Perlis","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1517\/14656566.8.1.13","article-title":"Bipolar depression: A review of randomised clinical trials","volume":"8","author":"Goodnick","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2008.02.011_bib6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.02.011_bib7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10401230209149099","article-title":"Extrapyramidal side effects of antipsychotic treatment: Scope of problem and impact on outcome","volume":"14","author":"Tandon","year":"2002","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib10","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: A comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4088\/JCP.v63n1206","article-title":"Predictors of noncompliance in patients with schizophrenia","volume":"63","author":"Perkins","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/10401230309085669","article-title":"Management of weight gain associated with antipsychotics","volume":"15","author":"Birt","year":"2003","journal-title":"Ann Clin Psychiatry"},{"issue":"Suppl 7","key":"10.1016\/j.clinthera.2008.02.011_bib13","first-page":"22","article-title":"Antipsychotic-induced weight gain: A review of literature","volume":"62","author":"Allison","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib14","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/oxfordjournals.schbul.a033504","article-title":"Prevalence and correlates of diabetes in national schizophrenia samples","volume":"26","author":"Dixon","year":"2000","journal-title":"Schizophr Bull"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2008.02.011_bib15","first-page":"S11","article-title":"Screening for type 2 diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2008.02.011_bib16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","article-title":"Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia","volume":"160","author":"Ryan","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1464-5491.2007.02092.x","article-title":"Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia","volume":"24","author":"Spelman","year":"2007","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2008.02.011_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.ijo.0801840","article-title":"Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia","volume":"26","author":"Thakore","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.clinthera.2008.02.011_bib19","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.lfs.2003.08.044","article-title":"The effects of atypical antipsy-chotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia [published correction appears in Life Sci. 2004;75: 2851]","volume":"74","author":"Ryan","year":"2004","journal-title":"Life Sci"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.02.011_bib20","first-page":"5","article-title":"Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity","volume":"55","author":"Leysen","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2008.02.011_bib22","series-title":"Poster presented at: 18th Annual Meeting of the European College of Neuro-psychopharmacology","article-title":"Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone ER in healthy subjects","author":"Karlsson","year":"2005"},{"key":"10.1016\/j.clinthera.2008.02.011_bib23","series-title":"Invega (paliperidone) [package insert]","year":"2007"},{"key":"10.1016\/j.clinthera.2008.02.011_bib24","series-title":"Essential Psychopharmacology: Neuroscientific Basis and Practical Applications","author":"Stahl","year":"2000"},{"key":"10.1016\/j.clinthera.2008.02.011_bib25","series-title":"Abilify (aripiprazole) [package insert]","year":"2006"},{"key":"10.1016\/j.clinthera.2008.02.011_bib26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fastdissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib27","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1176\/appi.ajp.162.10.1984-a","article-title":"An update of fast-off dopamine D2 atypical antipsychotics","volume":"162","author":"Seeman","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2008.02.011_bib29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week randomized, placebo-controlled study [published correction appears in Schizophr Res. 2007;96:273-274]","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2008.02.011_bib30","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":"Efficacy and safety of paliperidone extended-release tablets: Results of a 6-week, randomized, placebo-controlled study","volume":"62","author":"Marder","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib31","series-title":"Poster presented at: 25th Biennial Congress ofthe Collegium Internationale Neuro-Psychopharma-cologium","article-title":"Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 6-week placebo-controlled studies","author":"Meltzer","year":"2006"},{"key":"10.1016\/j.clinthera.2008.02.011_bib32","series-title":"Poster presented at: 2006 US Psychiatric Mental Health Congress","article-title":"Effects of paliperidone extended-release tablets on prolactin exposure in patients with stable schizophrenia","author":"Eeredekens","year":"2006"},{"key":"10.1016\/j.clinthera.2008.02.011_bib33","series-title":"Poster presented at: 46th Annual Meeting of the New Clinical Drug Evaluation Unit","article-title":"Effects of hepatic impairment on the pharmacokinetics of paliperidone immediate release","author":"Thyssen","year":"2006"},{"key":"10.1016\/j.clinthera.2008.02.011_bib34","series-title":"Poster presented at: Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics","article-title":"Metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects","author":"Vermeir","year":"2006"},{"key":"10.1016\/j.clinthera.2008.02.011_bib36","series-title":"Presented at: 160th Annual Meeting of the American Psychiatric Association","article-title":"A randomized, open label, single center, crossover study of the potential effects of paroxetine on the pharmacokinetics of a single dose of paliperidone extended release tablets in healthy subjects","author":"Berwaerts","year":"2007"},{"key":"10.1016\/j.clinthera.2008.02.011_bib37","doi-asserted-by":"crossref","first-page":"P22","DOI":"10.1016\/j.clpt.2005.12.079","article-title":"PI-58 No pharmacokinetic interaction between trimethoprim and paliperidone ER in healthy subjects","volume":"79","author":"Cleton","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.02.011_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":"Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study [published correction appears in J Clin Psychopharmacol. 2007;27:258]","volume":"27","author":"Kramer","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2008.02.011_bib39","series-title":"Poster presented at: 159th Annual Meeting of the American Psychiatric Association","article-title":"A 6-week placebo-controlled study on the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients","author":"Kramer","year":"2006"},{"key":"10.1016\/j.clinthera.2008.02.011_bib40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.clinthera.2008.02.011_bib41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2008.02.011_bib42","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials [published correction appears in J Clin Psychiatry. 1998;59:200]","volume":"58","author":"Marder","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2008.02.011_bib43","series-title":"ECDEU Assessment Manual for Psychopharmacology","first-page":"218","year":"1976"},{"key":"10.1016\/j.clinthera.2008.02.011_bib44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.clinthera.2008.02.011_bib45","series-title":"Poster presented at: 2007 International Congress of Schizophrenia Research","article-title":"Effects of paliperidone ER in patients with schizophrenia previously treated with risperidone","author":"Canuso","year":"2007"},{"key":"10.1016\/j.clinthera.2008.02.011_bib46","series-title":"Poster presented at: 2007 International Congress of Schizophrenia Research","article-title":"Effects of paliperidone ER in patients with schizophrenia previously treated with olanzapine","author":"Dirks","year":"2007"},{"key":"10.1016\/j.clinthera.2008.02.011_bib47","series-title":"Poster presented at: 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists","article-title":"Paliperidone extended-release in patients with schizophrenia previously treated with antipsychotic polypharmacy","author":"Schreiner","year":"2007"},{"key":"10.1016\/j.clinthera.2008.02.011_bib48","series-title":"Poster presented at: 25th Biennial Congress of the Collegium Internationale Neuro-Psychopharmacologium","article-title":"Paliperidone extended-release tablets in patients recently diagnosed with schizophrenia","author":"Kostic","year":"2006"},{"key":"10.1016\/j.clinthera.2008.02.011_bib49","series-title":"Poster presented at: 58th Annual Meeting of the American Psychiatric Association Institute on Psychiatric Services","article-title":"Paliperidone extended-release in severely ill patients with schizophrenia","author":"Canuso","year":"2006"},{"key":"10.1016\/j.clinthera.2008.02.011_bib50","series-title":"Poster presented at: 47th Annual Meeting of the New Clinical Drug Evaluation Unit","article-title":"Paliperidone extended-release in patients with schizophrenia and prominent affective symptoms","author":"Bossie","year":"2007"},{"key":"10.1016\/j.clinthera.2008.02.011_bib51","series-title":"Poster presented at: 25th Biennial Congress of the Collegium Internationale Neuro-Psychopharmacologium","article-title":"Efficacy of paliperidone extended-release tablets in patients with schizophrenia and predominant negative symptoms","author":"Dirks","year":"2006"},{"key":"10.1016\/j.clinthera.2008.02.011_bib52","series-title":"Poster presented at: 159th Annual Meeting of the American Psychiatric Association","article-title":"Direct and indirect effects of paliperidone extended-release tablets on negative symptoms in patients with schizophrenia","author":"Dirks","year":"2006"},{"key":"10.1016\/j.clinthera.2008.02.011_bib53","series-title":"Poster presented at: 45th Annual Meeting of the American College of Neuro-psychopharmacology","article-title":"A \"virtual\" comparison of paliperidone ER and oral risperidone in patients with schizophrenia","author":"Schooler","year":"2006"},{"key":"10.1016\/j.clinthera.2008.02.011_bib54","series-title":"Poster presented at: 2007 International Congress of Schizophrenia Research","article-title":"Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 52-week, open-label extension studies","author":"Eerdekens","year":"2007"},{"key":"10.1016\/j.clinthera.2008.02.011_bib56","series-title":"Basic and Clinical Pharmacology","first-page":"141","article-title":"Adrenoceptor antagonist drugs","author":"Hoffman","year":"2007"},{"key":"10.1016\/j.clinthera.2008.02.011_bib57","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","article-title":"Clozapine, diabetes mellitus, weight gain and lipid abnormalities: A five-year naturalistic study","volume":"157","author":"Henderson","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2008.02.011_bib58","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2008.02.011_bib59","series-title":"RED BOOK for Windows on CD-ROM","year":"2008"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808000945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808000945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T20:11:41Z","timestamp":1684354301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808000945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0149291808000945"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.02.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}